Atomwise AI Superplatform
ML-powered platform exploring chemical space to discover novel, drug-like molecules
Platform · OtherCompany source
Company profile
About Atomwise
Atomwise is a drug discovery company that leverages machine learning to revolutionize how small-molecule drugs are discovered. The company's AI superplatform explores the vast universe of chemical space to identify novel, drug-like molecules that remain unseen by traditional discovery methods. Atomwise combines advanced artificial intelligence with world-class scientific and engineering expertise to accelerate the discovery of breakthrough therapeutics. The company's internal pipeline focuses on immune and inflammatory diseases, with programs designed to deliver first- and best-in-class therapeutic potential. By applying machine learning to drug hunting, Atomwise aims to dramatically reduce the time and cost associated with traditional drug discovery while increasing the probability of identifying successful drug candidates. The company represents a new generation of AI-native biotechnology firms that are fundamentally transforming pharmaceutical research and development through computational approaches.
Company description Atomwise official website
Primary marketDrug Discovery & Development
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Atomwise?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Immune diseases
- Inflammatory diseases
Who it serves
- Pharma
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy.Scientific reports · Jun 16, 2026
Screening for novel chemical scaffolds targeting PCNA identifies the Hsp90alpha inhibitor SNX-2112.Current research in structural biology · Jun 1, 2026
A Novel Triose Phosphate Isomerase Inhibitor With Dual Trypanosomicidal Activity was Identified Using Artificial Intelligence-Based Virtual Screening.ChemMedChem · Apr 28, 2026
Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy.bioRxiv : the preprint server for biology · Mar 17, 2026
Novel Small-Molecule Analogues of IU1 Ameliorate Amyloid-β Mediated Toxicity in Alzheimer's Disease Cell and Worm Models.International journal of molecular sciences · Feb 18, 2026
SHIPi improves hematologic recovery after chemotherapy.Molecular medicine (Cambridge, Mass.) · Oct 21, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Novel molecule discovery
Discovery of drug-like molecules unseen by traditional methods
First- and best-in-class potential
Programs targeting immune and inflammatory diseases
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Atomwise
Recent articles published on Atomwise's official website.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Drug Discovery & Development
Companies using AI, machine learning, or computational biology to discover new drug candidates, identify drug targets, predict drug efficacy, or accelerate pharmaceutical development. Includes both small molecule and biologics development, precision oncology drug discovery, and AI-driven target identification and molecule design.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.